MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock under the...
$6,812K
Exercise of warrants and
options
$2,514K
Net cash provided by
(used in) financing...
$9,326K
Net increase
(decrease) in cash and cash...
-$5,080K
Canceled cashflow
$9,326K
Share-based compensation
$2,297K
Depreciation
$1,465K
Financial (income)
expenses, net
-$606K
Changes in deferred
income tax asset
$340K
Increase in accounts
payable and accruals
$292K
Changes in accrued
liability for employee...
$22K
Short-term deposit
withdrawal
$5,000K
Net cash provided by
(used in) operating...
-$11,993K
Canceled cashflow
$5,022K
Net cash provided by
(used in) investing...
-$2,366K
Effect of exchange rate
changes on cash and cash...
-$47K
Canceled cashflow
$5,000K
Net income (loss)
-$6,604K
Decrease (increase) in
accounts...
$5,890K
Increase in inventories
$4,486K
Gain on amounts
funded in respect of...
$20K
Changes in operating
lease right of use...
$15K
Investment in bank deposits
$5,000K
Purchase of property and
equipment
$1,638K
Increase in restricted
deposit
$702K
Amounts paid (funded) in
respect of employee...
$26K
Back
Back
Cash Flow
source: myfinsight.com
Protalix BioTherapeutics, Inc. (PLX)
Protalix BioTherapeutics, Inc. (PLX)